The company said Friday it develops medicines designed to precisely target disease pathology with an initial emphasis on the innate immune system. Odyssey said its most advanced programs include ...
In a report released today, Inigo Vega from Jefferies reiterated a Buy rating on Nu Holdings (NU – Research Report). The company’s shares ...
Jefferies analyst Stephen Volkmann maintained a Buy rating on Ingersoll Rand (IR – Research Report) yesterday and set a price target of ...
TOKYO: Japan's Nintendo said on Thursday it will release the Switch 2 console this year, unveiling a device that appeared to ...
Presentation Operator Good morning, and welcome to UnitedHealth Group Fourth Quarter and Full Year 2024 Earnings Conference ...